Page last updated: 2024-11-06

lobaric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lobaric acid is a lichen secondary metabolite that has been shown to exhibit a variety of biological activities, including antifungal, antibacterial, and antiviral properties. It has also been shown to have antioxidant and cytotoxic effects. Lobaric acid is synthesized by lichens through a complex biosynthetic pathway that involves the condensation of two polyketide molecules. The compound is found in a variety of lichen species, including Lobaria pulmonaria, which is commonly known as lungwort. Lobaric acid is studied for its potential medicinal properties, as well as its role in the ecology of lichens. The compound is thought to play a role in the defense of lichens against herbivores and pathogens. It is also thought to be involved in the symbiotic relationship between lichens and their fungal partners.'

lobaric acid: inhibits formation of leukotrienes C4, D4, and E4; also reduces muscle contraction; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73157
CHEMBL ID551842
CHEBI ID93548
SCHEMBL ID3910434
MeSH IDM0272751

Synonyms (49)

Synonym
8-hydroxy-3-methoxy-11-oxo-1-pentanoyl-6-pentyl-11h-dibenzo[b,e][1,4]dioxepine-7-carboxylic acid
BRD-K88849294-001-02-1
SDCCGMLS-0066497.P001
MLS001049101
smr000386933
SPECTRUM_000626
BSPBIO_002793
SPECTRUM5_000025
11h-dibenzo[b,e][1,4]dioxepin-7-carboxylic acid, 8-hydroxy-3-methoxy-11-oxo-1-(1-oxopentyl)-6-pentyl-
lobaric acid
522-53-2
NCGC00095570-01
KBIOSS_001106
KBIOGR_001925
KBIO2_003674
KBIO3_002293
KBIO2_001106
KBIO2_006242
SPECTRUM2_000310
SPBIO_000280
SPECTRUM3_001177
SPECTRUM4_001443
SPECTRUM300018
NCGC00095570-02
bdbm50294526
CHEMBL551842 ,
3-hydroxy-9-methoxy-6-oxo-7-pentanoyl-1-pentylbenzo[b][1,4]benzodioxepine-2-carboxylic acid
cid_73157
HMS2271L13
AKOS015969735
CCG-38587
11h-dibenzo(b,e)(1,4)dioxepin-7-carboxylic acid, 8-hydroxy-3-methoxy-11-oxo-1-(1-oxopentyl)-6-pentyl-
SCHEMBL3910434
REGID_FOR_CID_73157
lobraric acid
JHEWMLHQNRHTQX-UHFFFAOYSA-N
stereocaulic acid
11h-dibenzo[b,e][1,4]dioxepin-7-carboxylic acid, 8-hydroxy-3-methoxy-11-oxo-6-pentyl-1-valeryl-
8-hydroxy-3-methoxy-11-oxo-1-pentanoyl-6-pentyl-11h-dibenzo[b,e][1,4]dioxepine-7-carboxylic acid #
lobutoic acid
DTXSID30200238
SR-01000758235-2
sr-01000758235
CHEBI:93548
np335
Q27165242
3-hydroxy-9-methoxy-6-oxo-7-(1-oxopentyl)-1-pentyl-2-benzo[b][1,4]benzodioxepincarboxylic acid
BRD-K88849294-001-08-8
STL578212

Research Excerpts

Effects

ExcerptReferenceRelevance
"Lobaric acid (1) has been isolated from lichen, Stereocaulon sasakii together with a new benzofuran, sakisacaulon A (2). "( Antimitotic activity of lobaric acid and a new benzofuran, sakisacaulon A from Stereocaulon sasakii.
Hirasawa, Y; Kishibe, K; Morita, H; Noya, S; Shiro, M; Tsuchiya, T, 2009
)
2.1

Toxicity

ExcerptReferenceRelevance
" Strikingly, in (Tm + La)-treated rats, all the observed adverse effects of Tm on the hormonal parameters, cell morphology, and the length of each phase of estrous cycle were significantly diminished in a dose-dependent manner."( Lobaric acid prevents the adverse effects of tetramethrin on the estrous cycle of female albino Wistar rats.
Annam, SSP; Nguyen, HT; Okello, E; Polimati, H; Tatipamula, VB; Thai, QM; Vu, TY, 2022
)
2.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carbonyl compoundAny compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (61)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency35.71680.125919.1169125.8920AID2549; AID504841
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
WRNHomo sapiens (human)Potency50.11870.168331.2583100.0000AID651768
USP1 protein, partialHomo sapiens (human)Potency66.89670.031637.5844354.8130AID504865; AID743255
GLS proteinHomo sapiens (human)Potency28.18380.35487.935539.8107AID624170
Microtubule-associated protein tauHomo sapiens (human)Potency28.18380.180013.557439.8107AID1460
TSHR proteinHomo sapiens (human)Potency25.37590.338119.046637.9330AID602292; AID602441
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency19.95260.00527.809829.0929AID588855
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency50.11876.309627.099079.4328AID602179
67.9K proteinVaccinia virusPotency5.01190.00018.4406100.0000AID720579
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency15.84890.016525.307841.3999AID602332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency67.83350.354828.065989.1251AID504847
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency39.81073.548119.542744.6684AID743266
DNA polymerase betaHomo sapiens (human)Potency50.11870.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency25.11890.039816.784239.8107AID995
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency39.81070.010323.856763.0957AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency17.78280.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency79.43280.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency28.18380.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency23.10930.004611.374133.4983AID624296
DNA polymerase kappa isoform 1Homo sapiens (human)Potency79.43280.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency25.11890.058010.694926.6086AID602310
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency50.11876.309660.2008112.2020AID720709
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency2.51191.995325.532750.1187AID624287
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency50.11873.981146.7448112.2020AID720708
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, RNA-directed RNA polymerase NS5Dengue virus 2 16681-PDK53IC50 (µMol)32.19002.370054.1398100.0000AID588689
Ubiquitin-like modifier activating enzyme 2Homo sapiens (human)IC50 (µMol)10.89500.620016.325590.4600AID2006; AID2018
SUMO1 activating enzyme subunit 1Homo sapiens (human)IC50 (µMol)10.89500.620016.325590.4600AID2006; AID2018
envelope glycoproteinHuman immunodeficiency virus 1IC50 (µMol)13.10002.200014.820082.2000AID1986
SUMO-conjugating enzyme UBC9Homo sapiens (human)IC50 (µMol)10.89500.620016.325590.4600AID2006; AID2018
high affinity choline transporter 1 isoform aHomo sapiens (human)IC50 (µMol)10.96480.00036.210228.8403AID504840
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)0.83500.00053.49849.7600AID1355292; AID424242
G-protein coupled receptor 35Homo sapiens (human)IC50 (µMol)4.54000.03001.39804.6600AID663960
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)IC50 (µMol)1.62180.10472.71957.0795AID977603
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)Ki1.25000.08002.46889.8000AID977604
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)IC50 (µMol)0.72440.05002.37979.7000AID977600
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)Ki0.40000.04401.36305.0000AID977601
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
recombinase AMycobacterium tuberculosis H37RvEC50 (µMol)8.52500.018023.2882287.6000AID434968; AID435010
G-protein coupled receptor 35Homo sapiens (human)EC50 (µMol)9.99500.00202.50079.8000AID663955; AID663956
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
replicative DNA helicaseMycobacterium tuberculosis H37RvAC507.59500.057030.7482325.3000AID449749; AID449750
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (72)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
cytoskeleton organizationG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationG-protein coupled receptor 35Homo sapiens (human)
chemokine-mediated signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityG-protein coupled receptor 35Homo sapiens (human)
negative regulation of neuronal action potentialG-protein coupled receptor 35Homo sapiens (human)
positive regulation of Rho protein signal transductionG-protein coupled receptor 35Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor activityG-protein coupled receptor 35Homo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (70)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1419103Antiinflammatory activity in human U937 cells assessed as inhibition Aggregatibacter actinomycetemcomitans LPS-induced IL-1beta secretion at 10 to 80 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELI2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1355292Inhibition of PTP1B (1 to 298 residues) (unknown origin) using p-nitrophenylphosphate as substrate after 30 mins2018Journal of natural products, 06-22, Volume: 81, Issue:6
Total Syntheses of Lobaric Acid and Its Derivatives from the Antarctic Lichen Stereocaulon alpinum.
AID663961Agonist activity at GPR35 receptor in human HT-29 cells assessed as shift in resonant wavelength of biosensor stimulation after 10 mins by dynamic mass redistribution assay relative to control2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID1419088Inhibition of TLR4 in human U937-3xkappaB-LUC cells assessed as inhibition of Aggregatibacter actinomycetemcomitans LPS-induced NF-kappaB activation preincubated for 30 mins followed by LPS stimulation and measured after 6 hrs post LPS challenge by Bright2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1320901Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2016Journal of natural products, 06-24, Volume: 79, Issue:6
Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis.
AID1419106Binding affinity to recombinant human PPARgamma LBD at 40 uM by TR-FRET based green polar-screen PPAR competitor assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1437932Antifungal activity against Candida albicans ATCC 28366 assessed as growth inhibition at 80 uM after 24 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
Dibenzofurans and Pseudodepsidones from the Lichen Stereocaulon paschale Collected in Northern Quebec.
AID424242Inhibition of PTP1B2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Protein tyrosine phosphatase 1B inhibitory effects of depsidone and pseudodepsidone metabolites from the Antarctic lichen Stereocaulon alpinum.
AID1419087Inhibition of TLR4 in human U937-3xkappaB-LUC cells assessed as inhibition of Aggregatibacter actinomycetemcomitans LPS-induced NF-kappaB activation at 5 uM preincubated for 30 mins followed by LPS stimulation and measured after 6 hrs post LPS challenge b2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419097Antiinflammatory activity in human U937 cells assessed as inhibition of LPS-induced IL-1beta production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419096Antiinflammatory activity in human U937 cells assessed as inhibition of LPS-induced IL-8 production at 10 to 20 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID663956Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID1419102Inhibition of TLR4 in human U937-3xkappaB-LUC cells assessed as inhibition of Escherichia coli LPS-induced NF-kappaB activation at 5 to 50 uM preincubated for 30 mins followed by LPS stimulation and measured after 6 hrs post LPS challenge by Bright-Glo lu2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419092Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha secretion at 10 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA relative to control2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID420571Inhibition of tubulin polymerization2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Antimitotic activity of lobaric acid and a new benzofuran, sakisacaulon A from Stereocaulon sasakii.
AID663963Agonist activity at GPR35 receptor in human HT-29 cells at 16 uM after 10 mins by dynamic mass redistribution assay in the presence of SPB051422012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID1437931Bactericidal activity against Streptococcus mutans ATCC 25175 after 24 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
Dibenzofurans and Pseudodepsidones from the Lichen Stereocaulon paschale Collected in Northern Quebec.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1437929Antibacterial activity against Streptococcus mutans ATCC 25175 after 24 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
Dibenzofurans and Pseudodepsidones from the Lichen Stereocaulon paschale Collected in Northern Quebec.
AID1419094Antiinflammatory activity in human U937 cells assessed as inhibition of LPS-induced IL-8 production at 40 to 80 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419093Antiinflammatory activity in human U937 cells assessed as inhibition of LPS-induced IL-6 production at 40 to 80 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419104Antiinflammatory activity in human U937 cells assessed as inhibition Aggregatibacter actinomycetemcomitans LPS-induced TNFalpha secretion at 10 to 80 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELI2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID424243Non competitive inhibition of PTP1B assessed as inhibition of substrate catalysis by Lineweaver-Burke plot2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Protein tyrosine phosphatase 1B inhibitory effects of depsidone and pseudodepsidone metabolites from the Antarctic lichen Stereocaulon alpinum.
AID1419100Antiinflammatory activity in human U937 cells assessed as inhibition of Escherichia coli LPS-induced IL-1beta secretion at 10 to 80 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID977604Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1419085Inhibition of TLR4 in human U937-3xkappaB-LUC cells assessed as inhibition of Aggregatibacter actinomycetemcomitans LPS-induced NF-kappaB activation at 20 uM preincubated for 30 mins followed by LPS stimulation and measured after 6 hrs post LPS challenge 2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419080Cytotoxicity against PMA-differentiated human U937 macrophages assessed as cell viability at 80 uM after 24 hrs by MTT assay relative to untreated control2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID663962Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay relative to control2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID1320900Cytotoxicity against human UM-UC-3 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2016Journal of natural products, 06-24, Volume: 79, Issue:6
Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis.
AID1437928Antibacterial activity against Porphyromonas gingivalis ATCC 33277 after 24 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
Dibenzofurans and Pseudodepsidones from the Lichen Stereocaulon paschale Collected in Northern Quebec.
AID1419081Cytotoxicity against PMA-differentiated human U937 macrophages assessed as cell viability at 40 uM after 24 hrs by MTT assay relative to untreated control2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419082Cytotoxicity against PMA-differentiated human U937 macrophages assessed as cell viability at 20 uM after 24 hrs by MTT assay relative to untreated control2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1419084Inhibition of TLR4 in human U937-3xkappaB-LUC cells assessed as inhibition of Aggregatibacter actinomycetemcomitans LPS-induced NF-kappaB activation at 50 uM preincubated for 30 mins followed by LPS stimulation and measured after 6 hrs post LPS challenge 2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419090Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha secretion at 40 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA relative to control2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID663960Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID977601Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977600pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1320899Cytotoxicity against human J82 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2016Journal of natural products, 06-24, Volume: 79, Issue:6
Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis.
AID1419101Antiinflammatory activity in human U937 cells assessed as inhibition of Escherichia coli LPS-induced TNFalpha secretion at 10 to 80 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1419091Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha secretion at 20 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA relative to control2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID663955Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.
AID977603pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1419105Inhibition of TLR4 in human U937-3xkappaB-LUC cells assessed as inhibition of Aggregatibacter actinomycetemcomitans LPS-induced NF-kappaB activation at 5 to 50 uM preincubated for 30 mins followed by LPS stimulation and measured after 6 hrs post LPS chall2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419083Cytotoxicity against PMA-differentiated human U937 macrophages assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to untreated control2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419089Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha secretion at 80 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA relative to control2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1320898Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2016Journal of natural products, 06-24, Volume: 79, Issue:6
Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis.
AID1419086Inhibition of TLR4 in human U937-3xkappaB-LUC cells assessed as inhibition of Aggregatibacter actinomycetemcomitans LPS-induced NF-kappaB activation at 10 uM preincubated for 30 mins followed by LPS stimulation and measured after 6 hrs post LPS challenge 2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1419095Antiinflammatory activity in human U937 cells assessed as inhibition of LPS-induced IL-8 production at 20 uM preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs post LPS challenge by ELISA2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Lobaric acid and pseudodepsidones inhibit NF-κB signaling pathway by activation of PPAR-γ.
AID1320902Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2016Journal of natural products, 06-24, Volume: 79, Issue:6
Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis.
AID1437930Bactericidal activity against Porphyromonas gingivalis ATCC 33277 after 24 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
Dibenzofurans and Pseudodepsidones from the Lichen Stereocaulon paschale Collected in Northern Quebec.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (9.38)18.2507
2000's4 (12.50)29.6817
2010's20 (62.50)24.3611
2020's5 (15.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.06 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]